Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration

Results of a phase I clinical trial

Peter A. Campochiaro, Quan Dong Nguyen, Syed Mahmood Shah, Michael Klein, Eric Holz, Robert N. Frank, David A. Saperstein, Anurag Gupta, J. Timothy Stout, Jennifer Macko, Robert DiBartolomeo, Lisa L. Wei

Research output: Contribution to journalArticle

274 Citations (Scopus)

Abstract

Twenty-eight patients with advanced neovascular age-related macular degeneration (AMD) were given a single intravitreous injection of an E1-, partial E3-, E4-deleted adenoviral vector expressing human pigment epithelium-derived factor (AdPEDF.11). Doses ranging from 106 to 109.5 particle units (PU) were investigated. There were no serious adverse events related to AdPEDF.11 and no dose-limiting toxicities. Signs of mild, transient intraocular inflammation occurred in 25% of patients, but there was no severe inflammation. Six patients experienced increased intraocular pressure that was easily controlled by topical medication. All adenoviral cultures were negative. At 3 and 6 months after injection, 55 and 50%, respectively, of patients treated with 106-107.5 PU and 94 and 71% of patients treated with 108-109.5 PU had no change or improvement in lesion size from baseline. The median increase in lesion size at 6 and 12 months was 0.5 and 1.0 disk areas in the low-dose group compared with 0 and 0 disk areas in the high-dose group. These data suggest the possibility of antiangiogenic activity that may last for several months after a single intravitreous injection of doses greater than 108 PU of AdPEDF.11. This study provides evidence that adenoviral vector-mediated ocular gene transfer is a viable approach for the treatment of ocular disorders and that further studies investigating the efficacy of AdPEDF.11 in patients with neovascular AMD should be performed.

Original languageEnglish (US)
Pages (from-to)167-176
Number of pages10
JournalHuman Gene Therapy
Volume17
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Clinical Trials, Phase I
Macular Degeneration
Injections
Inflammation
Intraocular Pressure
pigment epithelium-derived factor
Genes

ASJC Scopus subject areas

  • Genetics

Cite this

Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration : Results of a phase I clinical trial. / Campochiaro, Peter A.; Nguyen, Quan Dong; Shah, Syed Mahmood; Klein, Michael; Holz, Eric; Frank, Robert N.; Saperstein, David A.; Gupta, Anurag; Stout, J. Timothy; Macko, Jennifer; DiBartolomeo, Robert; Wei, Lisa L.

In: Human Gene Therapy, Vol. 17, No. 2, 02.2006, p. 167-176.

Research output: Contribution to journalArticle

Campochiaro, PA, Nguyen, QD, Shah, SM, Klein, M, Holz, E, Frank, RN, Saperstein, DA, Gupta, A, Stout, JT, Macko, J, DiBartolomeo, R & Wei, LL 2006, 'Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial', Human Gene Therapy, vol. 17, no. 2, pp. 167-176. https://doi.org/10.1089/hum.2006.17.167
Campochiaro, Peter A. ; Nguyen, Quan Dong ; Shah, Syed Mahmood ; Klein, Michael ; Holz, Eric ; Frank, Robert N. ; Saperstein, David A. ; Gupta, Anurag ; Stout, J. Timothy ; Macko, Jennifer ; DiBartolomeo, Robert ; Wei, Lisa L. / Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration : Results of a phase I clinical trial. In: Human Gene Therapy. 2006 ; Vol. 17, No. 2. pp. 167-176.
@article{d75c0659bc4144398e9f16c433748778,
title = "Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial",
abstract = "Twenty-eight patients with advanced neovascular age-related macular degeneration (AMD) were given a single intravitreous injection of an E1-, partial E3-, E4-deleted adenoviral vector expressing human pigment epithelium-derived factor (AdPEDF.11). Doses ranging from 106 to 109.5 particle units (PU) were investigated. There were no serious adverse events related to AdPEDF.11 and no dose-limiting toxicities. Signs of mild, transient intraocular inflammation occurred in 25{\%} of patients, but there was no severe inflammation. Six patients experienced increased intraocular pressure that was easily controlled by topical medication. All adenoviral cultures were negative. At 3 and 6 months after injection, 55 and 50{\%}, respectively, of patients treated with 106-107.5 PU and 94 and 71{\%} of patients treated with 108-109.5 PU had no change or improvement in lesion size from baseline. The median increase in lesion size at 6 and 12 months was 0.5 and 1.0 disk areas in the low-dose group compared with 0 and 0 disk areas in the high-dose group. These data suggest the possibility of antiangiogenic activity that may last for several months after a single intravitreous injection of doses greater than 108 PU of AdPEDF.11. This study provides evidence that adenoviral vector-mediated ocular gene transfer is a viable approach for the treatment of ocular disorders and that further studies investigating the efficacy of AdPEDF.11 in patients with neovascular AMD should be performed.",
author = "Campochiaro, {Peter A.} and Nguyen, {Quan Dong} and Shah, {Syed Mahmood} and Michael Klein and Eric Holz and Frank, {Robert N.} and Saperstein, {David A.} and Anurag Gupta and Stout, {J. Timothy} and Jennifer Macko and Robert DiBartolomeo and Wei, {Lisa L.}",
year = "2006",
month = "2",
doi = "10.1089/hum.2006.17.167",
language = "English (US)",
volume = "17",
pages = "167--176",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration

T2 - Results of a phase I clinical trial

AU - Campochiaro, Peter A.

AU - Nguyen, Quan Dong

AU - Shah, Syed Mahmood

AU - Klein, Michael

AU - Holz, Eric

AU - Frank, Robert N.

AU - Saperstein, David A.

AU - Gupta, Anurag

AU - Stout, J. Timothy

AU - Macko, Jennifer

AU - DiBartolomeo, Robert

AU - Wei, Lisa L.

PY - 2006/2

Y1 - 2006/2

N2 - Twenty-eight patients with advanced neovascular age-related macular degeneration (AMD) were given a single intravitreous injection of an E1-, partial E3-, E4-deleted adenoviral vector expressing human pigment epithelium-derived factor (AdPEDF.11). Doses ranging from 106 to 109.5 particle units (PU) were investigated. There were no serious adverse events related to AdPEDF.11 and no dose-limiting toxicities. Signs of mild, transient intraocular inflammation occurred in 25% of patients, but there was no severe inflammation. Six patients experienced increased intraocular pressure that was easily controlled by topical medication. All adenoviral cultures were negative. At 3 and 6 months after injection, 55 and 50%, respectively, of patients treated with 106-107.5 PU and 94 and 71% of patients treated with 108-109.5 PU had no change or improvement in lesion size from baseline. The median increase in lesion size at 6 and 12 months was 0.5 and 1.0 disk areas in the low-dose group compared with 0 and 0 disk areas in the high-dose group. These data suggest the possibility of antiangiogenic activity that may last for several months after a single intravitreous injection of doses greater than 108 PU of AdPEDF.11. This study provides evidence that adenoviral vector-mediated ocular gene transfer is a viable approach for the treatment of ocular disorders and that further studies investigating the efficacy of AdPEDF.11 in patients with neovascular AMD should be performed.

AB - Twenty-eight patients with advanced neovascular age-related macular degeneration (AMD) were given a single intravitreous injection of an E1-, partial E3-, E4-deleted adenoviral vector expressing human pigment epithelium-derived factor (AdPEDF.11). Doses ranging from 106 to 109.5 particle units (PU) were investigated. There were no serious adverse events related to AdPEDF.11 and no dose-limiting toxicities. Signs of mild, transient intraocular inflammation occurred in 25% of patients, but there was no severe inflammation. Six patients experienced increased intraocular pressure that was easily controlled by topical medication. All adenoviral cultures were negative. At 3 and 6 months after injection, 55 and 50%, respectively, of patients treated with 106-107.5 PU and 94 and 71% of patients treated with 108-109.5 PU had no change or improvement in lesion size from baseline. The median increase in lesion size at 6 and 12 months was 0.5 and 1.0 disk areas in the low-dose group compared with 0 and 0 disk areas in the high-dose group. These data suggest the possibility of antiangiogenic activity that may last for several months after a single intravitreous injection of doses greater than 108 PU of AdPEDF.11. This study provides evidence that adenoviral vector-mediated ocular gene transfer is a viable approach for the treatment of ocular disorders and that further studies investigating the efficacy of AdPEDF.11 in patients with neovascular AMD should be performed.

UR - http://www.scopus.com/inward/record.url?scp=32944481724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944481724&partnerID=8YFLogxK

U2 - 10.1089/hum.2006.17.167

DO - 10.1089/hum.2006.17.167

M3 - Article

VL - 17

SP - 167

EP - 176

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 2

ER -